## CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

Yasuhiro Oki,<sup>1</sup> Kevin R Kelly,<sup>2</sup> Ian Flinn,<sup>3</sup> Manish R. Patel,<sup>3,4</sup> Robert Gharavi,<sup>5</sup> Anna Ma,<sup>5</sup> Jefferson Parker,<sup>5</sup> Amir Hafeez,<sup>5</sup> David Tuck<sup>5</sup> and Anas Younes<sup>6</sup>

<sup>1</sup>Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; <sup>2</sup>Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Los Angeles, CA; <sup>3</sup>Sarah Cannon Research Institute, Nashville, TN; <sup>4</sup>Florida Cancer Specialists, Sarasota, FL; <sup>5</sup>Curis Inc., Lexington, MA and <sup>6</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA

©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.172882

Received: May 30, 2017.

Accepted: August 29, 2017.

Pre-published: August 31, 2017.

Correspondence: rgharavi@curis.com


Supplemental Table 1 - Mean (standard deviation) CUDC-907 and Major Metabolite Plasma Pharmacokinetic Parameters

Time point	C <sub>max</sub> , (ng/mL)	$T_{\text{max},}(h)$	AUC <sub>0-24h</sub> (ng · h/mL)	$t_{1/2}(h)$
CUDC-907				
Day 1 (n=32 <sup>†</sup> )	11.2 (10.1)	2.17 (1.51)	37.8 (43.1)	2.86 (1.70)
Day 15 (n=25 <sup>‡</sup> )	9.19 (6.07)	1.98 (1.25)	24.5 (20.1)	3.89 (4.90)
CUDC-907 M1				
Day 1 (n=32)	17.5 (13.2)	20.8 (6.90)	248 (175)	N/A
Day 15 (n=26)	23.6 (19.0)	16.2 (10.2)	374 (315)	N/A
CUDC-907 M2				
Day 1 (n=32)	39.4 (29.7)	23.5 (2.83)	444 (291)	N/A
Day 15 (n=26)	42.6 (35.7)	20.5 (7.53)	567 (463)	N/A

 $C_{max}$ , maximal plasma concentration during dosing interval;  $T_{max}$ , time of maximal plasma concentration;  $AUC_{0-24h}$ , area under the plasma concentration v time curve from 0 to 24 hour;  $t_{1/2}$ , plasma elimination half-life

†On Day 1, number of patients for determination of  $C_{max}$ ,  $T_{max}$ ,  $AUC_{0-24h}$  and  $t_{1/2}$  were 32, 32, 32 and 23, respectively.

‡On Day 15, number of patients for determination of  $C_{max}$ ,  $T_{max}$ ,  $AUC_{0-24h}$  and  $t_{1/2}$  were 26, 25, 26 and 12, respectively.



Day 15

